The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study

Journal of the American College of Cardiology

Volumn 46, Issue 5, 2005, Pages 770-775

  Fossum, Eigil ^a   Moan, Andreas ^b   Kjeldsen, Sverre E ^a,c   Devereux, Richard B ^d   Julius, Stevo ^c   Snapinn, Steven M ^e   Edelman, Jonathan M ^e   De Faire, Ulf ^f   Fyhrquist, Frej ^g   Ibsen, Hans ^h   Kristianson, Krister ⁱ   Lederballe Pedersen, Ole ^j   Lindholm, Lars H ^k   Nieminen, Markku S ^g   Omvik, Per ^l   Oparil, Suzanne ^m   Wedel, Hans ⁿ   Dahlöf, Björn ^o  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b MSD   (Norway)

^c UNIVERSITY OF MICHIGAN   (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

ⁱ Merck Research Laboratories Scandinavia   (Sweden)

^j VIBORG HOSPITAL   (Denmark)

^k UMEÅ UNIVERSITY   (Sweden)

^l HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^m University of Alabama at Birmingham   (United States)

ⁿ NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^o SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; LOSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DEATH; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASPIRIN; ATENOLOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; TREATMENT OUTCOME;

EID: 24044551419     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.05.060     Document Type: Article

References (18)

1. B. Dahlöf, R. Devereux, U. de Faire The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group Am J Hypertens 10 1997 705 713
2. P.B. Timmermans Angiotensin II receptor antagonists an emerging new class of cardiovascular therapeutics Hypertens Res 22 1999 147 153
3. B. Dahlöf, S.E. Keller, L. Makris, A.I. Goldberg, C.S. Sweet, N.Y. Lim Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension Am J Hypertens 8 1995 578 583
4. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaboration Group Lancet 2 1986 57 66
5. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 995 1003
6. A.S. Al-Khadra, D.N. Salem, W.M. Rand, J.E. Udelson, J.J. Smith, M.A. Konstam Antiplatelet agents and survival a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial J Am Coll Cardiol 31 1998 419 425
7. K.N. Nguyen, I. Aursnes, J. Kjekshus Interaction between enalapril and aspirin on mortality after acute myocardial infarction subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) Am J Cardiol 79 1997 115 119
8. A. Zanchetti, L. Hansson, G. Leonetti, K.H. Rahn Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy J Hypertens 20 2002 1015 1022
9. E.Z. Fisman, E. Grossman, M. Motro, A. Tenebaum Clinical evidence of dose-dependent interaction between aspirin and angiotensin-converting enzyme inhibitors J Hum Hypertens 16 2002 379 383
10. K.K. Teo, S. Yusuf, M. Pfeffer Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin a systematic review Lancet 360 2002 1037 1043
11. B Dahlöf, R.B. Devereux, S. Julius Characteristics of 9,194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension Hypertension 32 1998 989 997
12. P.M. Okin, M.J. Roman, R.B. Devereux, P. Kligfield Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products J Am Coll Cardiol 25 1995 417 423
13. K.M. Anderson, P.W. Wilson, P.M. Odell, W.B. Kannel An updated coronary risk profile. A statement for health professionals Circulation 83 1991 356 362
14. J.J. Nawarskas, R.R. Townsend, M.D. Cirigliano, S.A. Spinler Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan Am J Hypertens 12 1999 784 789
15. B.Q. Zhu, R.E. Sievers, A.E. Browne Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function J Renin Angiotensin Aldosteron Syst 4 2003 31 37
16. F.A. le Noble, L.C. Kessels-van Wylick, W.J. Hacking, D.W. Slaaf, M.G. oude Egbrink, H.A. Struijker-Boudier The role of angiotensin II and prostaglandins in arcade formation in a developing microvascular network J Vasc Res 33 1996 480 488
17. P. Gohlke, C. Pees, T. Unger AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism Hypertension 31 1998 349 355
18. M. de Gasparo, H.M. Siragy The AT2 receptor fact, fancy and fantasy Regul Peptides 81 1999 11 24